Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gynecology & Urology

NICE wants more info on Roche's MabThera for rare autoimmune disease

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, is so far "minded not" to recommend Roche's MabThera (rituximab) for National Health Service patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. However, Roche could still convince the institute to, say yes. It has asked for more information from ahead of the next appraisal meeting on 28 August .

Table

View full table

Topics

Tags:
Gynecology & Urology
Latest Headlines

Podcast: Facilitating Patient Monitoring in CAR-T Development

Stock Watch: Novartis And The Changing Face Of Big Pharma

Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field

Quick Listen: Scrip's Five Must-Know Things

See All
UsernamePublicRestriction

Register

SC022181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By